DOCSLIB.ORG

Statistical Analysis Plan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Statistical Analysis Plan Cl a d ri bi n e Integrate d A n al ysis P l a n E M R700568 -012 Integrated Analysis Plan Cli ni c al St u dy P r ot o c ol E M R700568-012 I d e ntifi c ati o n N o. Titl e Pr os p e cti v e o bs er v ati o n al long -t er m s af et y r e gistr y of M ulti pl e S cl er osis p ati e nts w h o h a v e p arti ci p at e d i n cl a dri bi n e cli ni c al trials (P R E MI E R E) Eudra CT Nu mber 2009-017978-21 Study Phase N o n -E x p eri m e nt al r e gistr y I n v esti g ati o n al M e di ci n al Cladribine Merck Europe 10 m g t a bl ets Pro d uct(s) Cl a dri bi n e is a n adenosine dea minase -r esist a nt a n al o g u e of deox yadenosine t h at e x erts its eff e ct i n M S vi a pr ol o n g e d suppression of peripheral ly mphocy t e c o u nts Cli ni c al St u dy P r ot o c ol 2 0 J ul y 2 0 1 6 / V ersi o n 4. 0 i n cl u di n g a m e n d m e nt N o. 2 Versio n Integrated Analysis Plan Coordinating Author A ut hor P P D Merck P P D F u ncti o n A ut h or P P D P P P P D D Integrated Analysis Plan 2 1 Nove mber 2018 / V ersi o n 1. 0 Date and Version Integrated Analysis Plan F u ncti o n Na me Revie wers P P D M erck P P D P P D Merck P P D P P D M erck P P D P P D , P P P P D P P D D P P D P P D P P D T his d o c u m e nt is t h e pr o p ert y of M er c k K G a A, D ar mst a dt, G er m a n y, or o n e of its affili at e d co mpanies. It is i nt e n d e d f or r estri ct e d us e o nl y a n d m a y n ot - i n f ull or p art - be passed on, reproduced, published or used without e x pr ess p er missi o n of M er c k K G a A, D ar mst a dt, G er m a n y or its affili at e. C o p y ri g ht © 2018 by Merck K Ga A, Dar mstadt, Ger many o r its affili at e. All ri g hts r es e r v e d. 1/ 1 3 4 1/ 1 3 5 Cl a d ri bi n e Integrate d A n al ysis P l a n E M R700568 -012 Approval Page Integrated Analysis Plan: E MR700568 -012 Prospective o bs er v ati o n al l o n g -ter m safet y r e gistr y of M ulti pl e S cl er osis p ati e nts w h o h a v e p arti ci p at e d i n cl a dri bi n e cli ni c al tri als ( P R E MI E R E) Merck Respons i bl e D ate Sig nat ure P P D Via EL D O R A D O approval process 2/ 1 3 4 2/ 1 3 5 Cladribine Integrated Analysis Plan EMR700568-012 1 Table of Contents Integrated Analysis Plan...................................................................................................... 1 Approval Page 2 1 Table of Contents ................................................................................. 3 2 List of Abbreviations and Definition of Terms.................................... 6 3 Modification History............................................................................ 7 4 Purpose of the Integrated Analysis Plan .............................................. 8 5 Objectives and Endpoints..................................................................... 8 6 Overview of Planned Analyses ............................................................ 9 6.1 Intermediate Analyses.......................................................................... 9 6.2 Final Analysis ...................................................................................... 9 7 Changes to the Planned Analyses in the Clinical Study Protocol...... 10 8 Protocol Deviations and Analysis Populations .................................. 12 8.1 Definition of Protocol Deviations and Analysis Sets......................... 12 8.2 Definition of Analysis Populations and Subgroups ........................... 12 9 General Specifications for Data Analyses.......................................... 13 9.1 Treatment groups ............................................................................... 13 9.2 Analysis Period .................................................................................. 14 9.3 Identification of patients .................................................................... 14 9.4 Dictionary coding............................................................................... 14 9.5 Study Day 1........................................................................................ 15 9.6 Registry Day 1 ................................................................................... 15 9.7 Baseline.............................................................................................. 15 9.8 End of clinical trial............................................................................. 15 9.9 Last date in PREMIERE .................................................................... 15 9.10 Last ALC date with value in PREMIERE ......................................... 15 9.11 Conversion factors ............................................................................. 15 9.12 Handling of missing data ................................................................... 16 9.13 Presentation of continuous and qualitative variables......................... 16 9.14 Significance level............................................................................... 16 9.15 Software(s) ......................................................................................... 16 10 Study Participants .............................................................................. 16 3/134 3/135 Cladribine Integrated Analysis Plan EMR700568-012 10.1 Disposition of Participants and Discontinuations .............................. 16 10.2 Protocol Deviations............................................................................ 18 11 Demographics and Other Baseline Characteristics............................ 18 11.1 Demographics .................................................................................... 18 11.2 Medical History.................................................................................. 19 12 Previous Medications or Medications/Procedures in PREMIERE .... 19 12.1 Previous medications ......................................................................... 19 12.2 Medications in PREMIERE............................................................... 19 12.2.1 Disease Modifying Drugs in PREMIERE.......................................... 20 12.3 Procedures in PREMIERE................................................................. 20 12.4 Handling of Partial dates for Medications ......................................... 20 13 Study intervention Compliance and Exposure................................... 21 14 Efficacy Analyses............................................................................... 21 15 Safety Analyses.................................................................................. 21 15.1 Primary Endpoints.............................................................................. 21 15.1.1 Serious Adverse Events Related to Cladribine .................................. 21 15.1.2 Blood and Lymphatic System Disorders ........................................... 22 15.1.3 Neoplasms Benign, Malignant, and Unspecified............................... 23 15.1.4 Lymphopenia...................................................................................... 23 15.2 Secondary Endpoints: Pregnancy....................................................... 26 15.3 Adverse Events................................................................................... 27 15.3.1 All Adverse Events ............................................................................ 27 15.3.2 Serious Adverse Events...................................................................... 27 15.4 Deaths, Other Serious Adverse Events, and Other Significant Adverse Events................................................................................... 28 15.4.1 Deaths................................................................................................. 28 15.5 Adverse Event of Special Interest...................................................... 28 15.5.1 AESI= Infections................................................................................ 28 15.5.2 AESI = Malignancies ......................................................................... 30 15.6 Handling of Missing or Partial AE Dates (onset, resolution date)..... 30 15.7 Clinical Laboratory Evaluation.......................................................... 30 15.8 Vital Signs.......................................................................................... 30 15.9 Other Safety or Tolerability Evaluations ........................................... 30 4/134 4/135 Cladribine Integrated Analysis Plan EMR700568-012 16 Analyses of Other Endpoints ............................................................. 31 17 References.......................................................................................... 31 18 Appendices......................................................................................... 32 18.1 Pregnancy and neonatal topics (SMQ 20000185).............................. 32 18.2 Adverse Events Related to Pregnancy ................................................. 1 18.3 AESI: Opportunistic Infections............................................................ 1 18.4 AESI Herpes Zoster ............................................................................. 3 18.5 Malignant or Unspecified Tumours (SMQ 20000091)........................ 4 18.6 AESI: Malignancies ............................................................................. 1 Table of Contents of Table Table 1 Changes from the planned analyses in the clinical study protocol .... 10 Table 2 Table header example ........................................................................ 13 Table 3 Identification
Load more

Recommended publications
  • Mimics, Miscalls, and Misses in Pancreatic Disease Koenraad J
    Mimics, Miscalls, and Misses in Pancreatic Disease Koenraad J. Mortelé1 The radiologist plays a pivotal role in the detection and This chapter will summarize, review, and illustrate the characterization of pancreatic disorders. Unfortunately, the most common and important mimics, miscalls, and misses in accuracy of rendered diagnoses is not infrequently plagued by pancreatic imaging and thereby improve diagnostic accuracy a combination of “overcalls” of normal pancreatic anomalies of diagnoses rendered when interpreting radiologic studies of and variants; “miscalls” of specific and sometimes pathog- the pancreas. nomonic pancreatic entities; and “misses” of subtle, uncom- mon, or inadequately imaged pancreatic abnormalities. Ba- Normal Pancreatic Anatomy sic understanding of the normal and variant anatomy of the The Gland pancreas, knowledge of state-of-the-art pancreatic imaging The coarsely lobulated pancreas, typically measuring ap- techniques, and familiarity with the most commonly made mis- proximately 15–20 cm in length, is located in the retroperito- diagnoses and misses in pancreatic imaging is mandatory to neal anterior pararenal space and can be divided in four parts: avoid this group of errors. head and uncinate process, neck, body, and tail [4]. The head, neck, and body are retroperitoneal in location whereas the Mimics of pancreatic disease, caused by developmental tail extends into the peritoneal space. The pancreatic head is variants and anomalies, are commonly encountered on imag- defined as being to the right of the superior mesenteric vein ing studies [1–3]. To differentiate these benign “nontouch” en- (SMV). The uncinate process is the prolongation of the medi- tities from true pancreatic conditions, radiologists should be al and caudal parts of the head; it has a triangular shape with a familiar with them, the imaging techniques available to study straight or concave anteromedial border.
    [Show full text]
  • Childhood Cerebral X-Linked Adrenoleukodystrophy with Atypical Neuroimaging Abnormalities and a No…
    9/28/2018 Journal of Postgraduate Medicine: Childhood cerebral X-linked adrenoleukodystrophy with atypical neuroimaging abnormalities and a no… Open access journal indexed with Index Medicus & EMBASE Home | Subscribe | Feedback [Download PDF] CASE REPORT Year : 2018 | Volume : 64 | Issue : 1 | Page : 59-63 Childhood cerebral X-linked adrenoleukodystrophy with atypical neuroimaging abnormalities and a novel mutation M Muranjan1, S Karande1, S Sankhe2, S Eichler3, 1 Department of Pediatrics, Seth GS Medical College and KEM Hospital, Parel, Mumbai, Maharashtra, India 2 Department of Radiology, Seth GS Medical College and KEM Hospital, Parel, Mumbai, Maharashtra, India 3 Centogene AG, Schillingallee 68, Rostock, Germany Correspondence Address: Dr. M Muranjan Department of Pediatrics, Seth GS Medical College and KEM Hospital, Parel, Mumbai, Maharashtra India Abstract Childhood cerebral X-linked adrenoleukodystrophy (XALD) typically manifests with symptoms of adrenocortical insufficiency and a variety of neurocognitive and behavioral abnormalities. A major diagnostic clue is the characteristic neuroinflammatory parieto-occipital white matter lesions on magnetic resonance imaging. This study reports a 5-year 10-month old boy presenting with generalized skin hyperpigmentation since 3 years of age. Over the past 9 months, he had developed right-sided hemiparesis and speech and behavioral abnormalities, which had progressed over 5 months to bilateral hemiparesis. Retrospective analyses of serial brain magnetic resonance images revealed an unusual pattern of lesions involving the internal capsules, corticospinal tracts in the midbrain and brainstem, and cerebellar white matter. The clinical diagnosis of childhood cerebral adrenoleukodystrophy was confirmed by elevated basal levels of adrenocorticotropin hormone and plasma very long chain fatty acid levels. Additionally, sequencing of the ABCD1 gene revealed a novel mutation.
    [Show full text]
  • Paternal Factors and Schizophrenia Risk: De Novo Mutations and Imprinting
    Paternal Factors and Schizophrenia Risk: De Novo Mutations and Imprinting by Dolores Malaspina Downloaded from https://academic.oup.com/schizophreniabulletin/article/27/3/379/1835092 by guest on 23 September 2021 Abstract (Impagnatiello et al. 1998; Kao et al. 1998), but there is no consensus that any particular gene plays a meaning- There is a strong genetic component for schizophrenia ful role in the etiology of schizophrenia (Hyman 2000). risk, but it is unclear how the illness is maintained in Some of the obstacles in genetic research in schiz- the population given the significantly reduced fertility ophrenia are those of any complex disorder, and include of those with the disorder. One possibility is that new incomplete penetrance, polygenic interaction (epista- mutations occur in schizophrenia vulnerability genes. sis), diagnostic instability, and variable expressivity. If so, then those with schizophrenia may have older Schizophrenia also does not show a clear Mendelian fathers, because advancing paternal age is the major inheritance pattern, although segregation analyses have source of new mutations in humans. This review variably supported dominant, recessive, additive, sex- describes several neurodevelopmental disorders that linked, and oligogenic inheritance (Book 1953; Slater have been associated with de novo mutations in the 1958; Garrone 1962; Elston and Campbell 1970; Slater paternal germ line and reviews data linking increased and Cowie 1971; Karlsson 1972; Stewart et al. 1980; schizophrenia risk with older fathers. Several genetic Risch 1990a, 1990fc; reviewed by Kendler and Diehl mechanisms that could explain this association are 1993). Furthermore, both nonallelic (Kaufmann et al. proposed, including paternal germ line mutations, 1998) and etiologic heterogeneity (Malaspina et al.
    [Show full text]
  • Bhagwan Moorjani, MD, FAAP, FAAN • Requires Knowledge of Normal CNS Developmental (I.E
    1/16/2012 Neuroimaging in Childhood • Neuroimaging issues are distinct from Pediatric Neuroimaging in adults Neurometabolic-degenerative disorder • Sedation/anesthesia and Epilepsy • Motion artifacts Bhagwan Moorjani, MD, FAAP, FAAN • Requires knowledge of normal CNS developmental (i.e. myelin maturation) • Contrast media • Parental anxiety Diagnostic Approach Neuroimaging in Epilepsy • Age of onset • Peak incidence in childhood • Static vs Progressive • Occurs as a co-morbid condition in many – Look for treatable causes pediatric disorders (birth injury, – Do not overlook abuse, Manchausen if all is negative dysmorphism, chromosomal anomalies, • Phenotype presence (syndromic, HC, NCS, developmental delays/regression) systemic involvement) • Predominant symptom (epilepsy, DD, • Many neurologic disorders in children weakness/motor, psychomotor regression, have the same chief complaint cognitive/dementia) 1 1/16/2012 Congenital Malformation • Characterized by their anatomic features • Broad categories: based on embryogenesis – Stage 1: Dorsal Induction: Formation and closure of the neural tube. (Weeks 3-4) – Stage 2: Ventral Induction: Formation of the brain segments and face. (Weeks 5-10) – Stage 3: Migration and Histogenesis: (Months 2-5) – Stage 4: Myelination: (5-15 months; matures by 3 years) Dandy Walker Malformation Dandy walker • Criteria: – high position of tentorium – dysgenesis/agenesis of vermis – cystic dilatation of fourth ventricle • commonly associated features: – hypoplasia of cerebellum – scalloping of inner table of occipital bone • associated abnormalities: – hydrocephalus 75% – dysgenesis of corpus callosum 25% – heterotropia 10% 2 1/16/2012 Etiology of Epilepsy: Developmental and Genetic Classification of Gray Matter Heterotropia Cortical Dysplasia 1. Secondary to abnormal neuronal and • displaced masses of nerve cells • Subependymal glial proliferation/apoptosis (gray matter) heterotropia (most • most common: small nest common) 2.
    [Show full text]
  • Duodenal Webs: an Experience with 18 Patients
    Journal of Neonatal Surgery 2012;1(2):20 O R I G I N A L A R T I C L E DUODENAL WEBS: AN EXPERIENCE WITH 18 PATIENTS Yogesh Kumar Sarin,* Akshay Sharma, Shalini Sinha, Vidyanand Pramod Deshpande Department of Pediatric Surgery, Maulana Azad Medical College, New Delhi-110002 * Corresponding Author Available at http://www.jneonatalsurg.com This work is licensed under a Creative Commons Attribution 3.0 Unported License How to cite: Sarin YK, Sharma A, Sinha S, Deshpande VP. Duodenal webs: an experience with 18 patients. J Neonat Surg 2012; 1: 20 ABSTRACT Aim: To describe the management and outcome of patients with duodenal webs, managed over a peri- od of 12 ½ years in our unit. Methods: It is a retrospective case series of 18 patients with congenital duodenal webs, managed in our unit, between 1999 and 2011. The medical record of these patients was retrieved and analyzed for demographic details, clinical presentation, associated anomalies, and outcome. Results: The median age of presentation was 8 days (range 1 day to 1.5 years). Antenatal diagnosis was made in only 2 (11.1%) patients. The commonest presentation was bilious vomiting. Associated anomalies were present in 8/18 patients, common being malrotation of gut. Down’s syndrome was seen in 2 patients and congenital heart disease in 1 patient. One patient had double duodenal webs. There was a delay in presentation of more than 5 days of life in 11/18 (61%) patients. Three patients who presented beyond neonatal age group had fenestrated duodenal membranes causing partial ob- struction.
    [Show full text]
  • Journal of Medical Genetics April 1992 Vol 29 No4 Contents Original Articles
    Journal of Medical Genetics April 1992 Vol 29 No4 Contents Original articles Beckwith-Wiedemann syndrome: a demonstration of the mechanisms responsible for the excess J Med Genet: first published as on 1 April 1992. Downloaded from of transmitting females C Moutou, C Junien, / Henry, C Bonai-Pellig 217 Evidence for paternal imprinting in familial Beckwith-Wiedemann syndrome D Viljoen, R Ramesar 221 Sex reversal in a child with a 46,X,Yp+ karyotype: support for the existence of a gene(s), located in distal Xp, involved in testis formation T Ogata, J R Hawkins, A Taylor, N Matsuo, J-1 Hata, P N Goodfellow 226 Highly polymorphic Xbol RFLPs of the human 21 -hydroxylase genes among Chinese L Chen, X Pan, Y Shen, Z Chen, Y Zhang, R Chen 231 Screening of microdeletions of chromosome 20 in patients with Alagille syndrome C Desmaze, J F Deleuze, A M Dutrillaux, G Thomas, M Hadchouel, A Aurias 233 Confirmation of genetic linkage between atopic IgE responses and chromosome 1 1 ql 3 R P Young, P A Sharp, J R Lynch, J A Faux, G M Lathrop, W 0 C M Cookson, J M Hopkini 236 Age at onset and life table risks in genetic counselling for Huntington's disease P S Harper, R G Newcombe 239 Genetic and clinical studies in autosomal dominant polycystic kidney disease type 1 (ADPKD1) E Coto, S Aguado, J Alvarez, M J Menendez-DIas, C Lopez-Larrea 243 Short communication Evidence for linkage disequilibrium between D16S94 and the adult onset polycystic kidney disease (PKD1) gene S E Pound, A D Carothers, P M Pignatelli, A M Macnicol, M L Watson, A F Wright 247 Technical note A strategy for the rapid isolation of new PCR based DNA polymorphisms P R Hoban, M F Santibanez-Koref, J Heighway 249 http://jmg.bmj.com/ Case reports Campomelic dysplasia associated with a de novo 2q;1 7q reciprocal translocation I D Young, J M Zuccollo, E L Maltby, N J Broderick 251 A complex chromosome rearrangement with 10 breakpoints: tentative assignment of the locus for Williams syndrome to 4q33-q35.1 R Tupler, P Maraschio, A Gerardo, R Mainieri G Lanzi L Tiepolo 253 on September 26, 2021 by guest.
    [Show full text]
  • 2016 IES Annual Meeting Final Programme
    ROYAL ACADEMY OF MEDICINE IN IRELAND IRISH JOURNAL OF MEDICAL SCIENCE Irish Endocrine Society 40th Annual Meeting 14th and 15th October 2016 Stormont Hotel, Belfast Local Organiser: Doctor Hamish Courtney, REVISEDRoyal Victoria Hospital, PROOF Belfast Irish Journal of Medical Science Volume XXX Supplement X DOI 10.1007/s11845-016-1482-y 123 123 Journal : Large 11845 Dispatch : 17-8-2016 Pages : 57 Article No. : 1482 h LE h TYPESET MS Code : 1482 h44CP h DISK Ir J Med Sci Disclosure statement This supplement is paid for by the Irish Endocrine Society. However the meeting costs are supported by the following commercial sponsors: Abbott Amgen Astra Zeneca Besins Healthcare BMS Boehringer Ingleheim Consilient Ipsen Janssen-Cilag Kyowa Kirin Lilly Menarini Merck Serono MSD Novartis Novo Nordisk Pfizer Sanofi REVISED PROOF 123 Journal : Large 11845 Dispatch : 17-8-2016 Pages : 57 Article No. : 1482 h LE h TYPESET MS Code : 1482 h44CP h DISK Ir J Med Sci Novo Lecture Nordisk Lecture 1976 D.K. O’Donovan 1977 S. Bloom 1978 J.H.S. Robertson 1979 A.G. Cudworth 1980 D.A.D. Montgomery 1981 Peter Watkins 1982 G. Joplin 1983 D.R. London 1984 A.X. Bertagna 1985 Malcolm Nattrass Laurence Kennedy 1986 Brian Frier JB Ferriss 1987 Maurice Scanlon TJ McKenna 1988 D.A. Heath AB Atkinson 1989 J. Ward GH Tomkin 1990 R. Volpe KD Buchanan 1991 Michael Besser PPA Smyth 1992 R.V. Ragontte DH Hadden 1993 Bruce Weintraub David Powell 1994 Oscar Croffard Patrick Bell 1995 Robert Lindsay Brian Sheridan 1996 C.R.W. Edwards Rosemary Freaney 1997 Stephanie Amiel David McCance 1998 Robert Turner Randle Hayes 1999 Ian Hay Sean K Cunningham 2000 Stephen O’Rahilly Michael Cullen 2001 Andre Lacroix Daphne Owens 2002 J.
    [Show full text]
  • Imaging Pearls of the Annular Pancreas on Antenatal Scan and Its
    Imaging pearls of the annular pancreas on antenatal scan and its diagnostic Case Report dilemma: A case report © 2020, Roul et al Pradeep Kumar Roul,1 Ashish Kaushik,1 Manish Kumar Gupta,2 Poonam Sherwani,1 * Submitted: 22-08-2020 Accepted: 10-09-2020 1 Department of Radiodiagnosis, All India Institute of Medical Sciences, Rishikesh 2 Department of Pediatric Surgery, All India Institute of Medical Sciences, Rishikesh License: This work is licensed under a Creative Commons Attribution 4.0 Correspondence*: Dr. Poonam Sherwani. DNB, EDIR, Fellow Pediatric Radiology, Department of International License. Radiodiagnosis, All India Institute of Medical Sciences, Rishikesh, E-mail: [email protected] DOI: https://doi.org/10.47338/jns.v9.669 KEYWORDS ABSTRACT Annular pancreas, Background: Annular pancreas is an uncommon cause of duodenal obstruction and rarely Duodenal obstruction, causes complete duodenal obstruction. Due to its rarity of identification in the antenatal Double bubble sign, period and overlapping imaging features with other causes of duodenal obstruction; it is Hyperechogenic band often misdiagnosed. Case presentation: A 33-year-old primigravida came for routine antenatal ultrasonography at 28 weeks and 4 days of gestational age. On antenatal ultrasonography, dilated duodenum and stomach were seen giving a double bubble sign and a hyperechoic band surrounding the duodenum. Associated polyhydramnios was also present. Fetal MRI was also done. Postpartum ultrasonography demonstrated pancreatic tissue surrounding the duodenum. The upper gastrointestinal contrast study showed a non-passage of contrast beyond the second part of the duodenum. Due to symptoms of obstruction, the neonate was operated on, and the underlying cause was found to be the annular pancreas.
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • RD-Action Matchmaker – Summary of Disease Expertise Recorded Under
    Summary of disease expertise recorded via RD-ACTION Matchmaker under each Thematic Grouping and EURORDIS Members’ Thematic Grouping Thematic Reported expertise of those completing the EURORDIS Member perspectives on Grouping matchmaker under each heading Grouping RD Thematically Rare Bone Achondroplasia/Hypochondroplasia Achondroplasia Amelia skeletal dysplasia’s including Achondroplasia/Growth hormone cleidocranial dysostosis, arthrogryposis deficiency/MPS/Turner Brachydactyly chondrodysplasia punctate Fibrous dysplasia of bone Collagenopathy and oncologic disease such as Fibrodysplasia ossificans progressive Li-Fraumeni syndrome Osteogenesis imperfecta Congenital hand and fore-foot conditions Sterno Costo Clavicular Hyperostosis Disorders of Sex Development Duchenne Muscular Dystrophy Ehlers –Danlos syndrome Fibrodysplasia Ossificans Progressiva Growth disorders Hypoparathyroidism Hypophosphatemic rickets & Nutritional Rickets Hypophosphatasia Jeune’s syndrome Limb reduction defects Madelung disease Metabolic Osteoporosis Multiple Hereditary Exostoses Osteogenesis imperfecta Osteoporosis Paediatric Osteoporosis Paget’s disease Phocomelia Pseudohypoparathyroidism Radial dysplasia Skeletal dysplasia Thanatophoric dwarfism Ulna dysplasia Rare Cancer and Adrenocortical tumours Acute monoblastic leukaemia Tumours Carcinoid tumours Brain tumour Craniopharyngioma Colon cancer, familial nonpolyposis Embryonal tumours of CNS Craniopharyngioma Ependymoma Desmoid disease Epithelial thymic tumours in
    [Show full text]
  • Diagnosis and Treatment of Jejunoileal Atresia
    World J. Surg. 17, 310-3! 7, 1993 WORLD Journal of SURGERY 1993 by the Soci›233 O Internationale de Chirurgie Diagnosis and Treatment of Jejunoileal Atresia Robert J. Touloukian, M.D. Department of Surgery, Section of Pediatric Surgery, Yale University School of Medicine, and the Yale-New Haven Hospital, New Haven, Connecticut, U.S.A. A total of 116 cases of intestinal atresia or stenosis were encountered at the Classification Yale-New Haven Hospital between 1970 and 1990. Sites involved were the duodenum (n = 61; 53%), jejunum or ileum (n = 47; 46%), and colon (n Duodenum = 8; 7%). Ail but two patients underwent operative correction, for an overall survival rate of 92 %. Challenging problems were the management Sixty-one patients with duodenal atresia or stenosis were en- of apple-peel atresia (rive patients), multiple intestinal atresia with countered, including 12 with preampullary duodenal obstruc- short-gut syndrome (eight patients), and proximal jejunal atresia with megaduodenum requiring imbrication duodenoplasty (four patients). tion based on the absence of bile in the gastric contents. A Major assets in the improved outlook for intestinal atresia are prenatal diaphragm causing partial obstruction or duodenal stenosis was diagnosis, regionalization of neonatal care, improved recognition of found in 14 patients. An unusual cause of obstruction is associated conditions, innovative surgical methods, and uncomplicated complete absence of a duodenal segment accompanied by a long-terre total parenteral nutrition. mesenteric defect--seen in rive patients. Detecting a "wind- sock" web is critical because there is a tendency to confuse it with distal duodenal obstruction and the frequent occurrence of Atresia is the m0st common cause of congenital intestinal an anomalous biliary duct entering along its medial margin [9, obstruction and accounts for about one-third of all cases of 10].
    [Show full text]
  • The Genetic Heterogeneity of Brachydactyly Type A1: Identifying the Molecular Pathways
    The genetic heterogeneity of brachydactyly type A1: Identifying the molecular pathways Lemuel Jean Racacho Thesis submitted to the Faculty of Graduate Studies and Postdoctoral Studies in partial fulfillment of the requirements for the Doctorate in Philosophy degree in Biochemistry Specialization in Human and Molecular Genetics Department of Biochemistry, Microbiology and Immunology Faculty of Medicine University of Ottawa © Lemuel Jean Racacho, Ottawa, Canada, 2015 Abstract Brachydactyly type A1 (BDA1) is a rare autosomal dominant trait characterized by the shortening of the middle phalanges of digits 2-5 and of the proximal phalange of digit 1 in both hands and feet. Many of the brachymesophalangies including BDA1 have been associated with genetic perturbations along the BMP-SMAD signaling pathway. The goal of this thesis is to identify the molecular pathways that are associated with the BDA1 phenotype through the genetic assessment of BDA1-affected families. We identified four missense mutations that are clustered with other reported BDA1 mutations in the central region of the N-terminal signaling peptide of IHH. We also identified a missense mutation in GDF5 cosegregating with a semi-dominant form of BDA1. In two families we reported two novel BDA1-associated sequence variants in BMPR1B, the gene which codes for the receptor of GDF5. In 2002, we reported a BDA1 trait linked to chromosome 5p13.3 in a Canadian kindred (BDA1B; MIM %607004) but we did not discover a BDA1-causal variant in any of the protein coding genes within the 2.8 Mb critical region. To provide a higher sensitivity of detection, we performed a targeted enrichment of the BDA1B locus followed by high-throughput sequencing.
    [Show full text]